REVB - Revere Bank Stock Price, Fair Value and News

2.08USD-0.24 (-10.34%)Market Closed

Market Summary

USD2.08-0.24

Market Closed

-10.34%

REVB Stock Price

View Fullscreen

REVB RSI Chart

REVB Valuation

Market Cap

13.1M

Price/Earnings (Trailing)

-130.98

Price/Sales (Trailing)

2.2K

Price/Free Cashflow

-1.8

REVB Price/Sales (Trailing)

REVB Profitability

Return on Equity

-1.52%

Return on Assets

-0.82%

Free Cashflow Yield

-55.63%

REVB Fundamentals

REVB Revenue

Revenue (TTM)

6.9K

REVB Earnings

Earnings (TTM)

-100.0K

Earnings Growth (Yr)

-80.74%

Earnings Growth (Qtr)

16.96%

Breaking Down REVB Revenue

Last 7 days

-22.1%

Last 30 days

-20%

Last 90 days

-18.3%

Trailing 12 Months

103.9%

How does REVB drawdown profile look like?

REVB Financial Health

Current Ratio

2.18

REVB Investor Care

Shares Dilution (1Y)

836.46%

Diluted EPS (TTM)

-0.09

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2021	2.9K	4.2K	5.6K	6.9K
2020	0	0	0	1.6K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Revere Bank

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Sep 28, 2023	tidmarsh george f	sold	-986	0.69	-1,429	-
Sep 18, 2023	tidmarsh george f	sold	-2,960	0.74	-4,000	-
Sep 15, 2023	tidmarsh george f	sold	-6,935	0.73	-9,500	-
Sep 14, 2023	tidmarsh george f	sold	-9,000	0.75	-12,000	-
Apr 18, 2023	tidmarsh george f	bought	29,000	1.16	25,000	-
Apr 17, 2023	tidmarsh george f	bought	30,740	1.16	26,500	-
Feb 25, 2022	tidmarsh george f	bought	32,000	1.6	20,000	-
Feb 09, 2022	tidmarsh george f	bought	76,599	2.5533	30,000	-
Feb 08, 2022	tidmarsh george f	bought	2,540	2.54	1,000	-
Feb 07, 2022	tidmarsh george f	bought	109,780	2.6076	42,100	-

Which funds bought or sold REVB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Feb 26, 2024	Privium Fund Management B.V.	unchanged	-	-278	466	-%
Feb 15, 2024	JANE STREET GROUP, LLC	unchanged	-	-315	530	-%
Feb 14, 2024	AXA S.A.	unchanged	-	-11,048	27,538	-%
Feb 14, 2024	Pine Valley Investments Ltd Liability Co	added	16.59	-1,134	3,087	-%
Feb 14, 2024	Walleye Capital LLC	unchanged	-	-1,178	1,982	-%
Feb 14, 2024	Walleye Capital LLC	added	5.61	-59,468	206,653	-%
Feb 14, 2024	CLEAR STREET LLC	sold off	-100	-	-	-%
Feb 14, 2024	SABBY MANAGEMENT, LLC	unchanged	-	-76,090,000	201,899,000	0.20%
Feb 14, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	sold off	-100	-8,561	-	-%
Feb 14, 2024	Walleye Trading LLC	unchanged	-	-661	1,113	-%

Are Funds Buying or Selling REVB?

Are funds buying REVB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own REVB

No. of Funds

Unveiling Revere Bank's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	lind global fund ii lp	2.9%	186,500	SC 13G/A
Feb 21, 2023	intracoastal capital, llc	4.99%	184,981	SC 13G
Feb 21, 2023	lind global fund ii lp	5.2%	186,500	SC 13G
Feb 14, 2023	axa im prime impact master fund i sca sicav-raif	8.32%	0	SC 13G
Feb 06, 2023	weiss asset management lp	0.00%	0	SC 13G/A
Jan 31, 2023	linden capital l.p.	2.8%	669,899	SC 13G/A
Aug 17, 2022	meteora capital, llc	0%	0	SC 13G/A

Recent SEC filings of Revere Bank

View All Filings

Date Filed	Form Type	Document
Apr 05, 2024	PRE 14A	PRE 14A
Mar 22, 2024	8-K	Current Report
Mar 22, 2024	10-K	Annual Report
Mar 12, 2024	8-K	Current Report
Feb 13, 2024	SC 13G/A	Major Ownership Report
Feb 12, 2024	SCHEDULE 13G/A	SCHEDULE 13G/A
Feb 08, 2024	8-K	Current Report
Feb 02, 2024	424B3	Prospectus Filed
Jan 31, 2024	EFFECT	EFFECT
Jan 30, 2024	S-1/A	Initial Public Offering

Revere Bank News

Latest updates

Revere Bank Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)					(In Thousands)
Description	(%) Q/Q	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Revenue	-36.8%	1.00	2.00	2.00	2.00	-
Operating Expenses	26.7%	3,857	3,044	2,442	2,608	137
S&GA Expenses	-21.2%	1,192	1,511	1,282	1,051	137
R&D Expenses	73.9%	2,665	1,533	1,160	1,557	-
Net Income	-26.8%	-3,860	-3,044	-2,469	-2,612	-1,621
Net Income Margin	0.7%	-1.74	-1.75	-1.58	-1.45	-1.03
Free Cashflow	-28.1%	-2,862	-2,234	-3,643	-2,481	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet															(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	-14.1%	12,213	14,219	16,039	18,119	5,503	6,601	4,154	7,980	40,768	73,555	73,888	74,028	4,620	3,499	-
Current Assets	-14.1%	12,148	14,147	15,961	18,035	5,413	6,505	4,051	7,871	1,912	39.00	374	515	4,620	3,499	23.00
Cash Equivalents	-14.3%	11,992	14,000	15,700	17,700	5,253	6,195	3,476	7,186	1,275	4,137	6,372	10,016	4,492	3,321	-
Net PPE	-8.8%	65.00	71.00	78.00	84.00	90.00	96.00	103	109	115	-	-	-	-	-	-
Liabilities	3.1%	5,565	5,400	4,624	8,101	4,451	4,374	5,997	8,078	2,142	6,649	6,224	5,032	1,209	3,486	-
Current Liabilities	3.1%	5,565	5,400	4,624	8,101	4,451	4,374	5,997	8,078	2,142	3,738	3,313	2,121	1,209	336	26.00
Shareholder's Equity	-25.2%	6,600	8,819	11,415	10,018	1,052	2,228	-	-	-99.47	3,655	6,568	8,906	6,936	13.00	5,538
Retained Earnings	-9.6%	-25,500	-23,264	-20,635	-19,200	-25,346	-24,139	-22,968	-21,133	-14,517	-6,604	-5,846	-4,515	-2,530	-12.19	-3.64
Additional Paid-In Capital	0.1%	32,115	32,076	32,044	29,201	26,399	26,343	21,110	21,020	14,418	-	-	-	5,536	23.00	-
Shares Outstanding	-100.0%	-	6,297	6,297	4,730	683	612	429	416	282	2,120	180	370	2,293	84.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	-16.7%	-2,002	-1,716	-1,991	-1,575	-947	-1,731	-3,710	-4,830	-2,878	-2,234	-3,594	-2,382	-208	-868*	-22.37	15.00
Share Based Compensation	0.0%	32.00	32.00	59.00	32.00	32.00	41.00	90.00	138	106	131	131	102	-	-	-	-
Cashflow From Investing	-	-	-	-	-	-	-	-	-	16.00	-	-49.01	-99.10	-	-	-	-
Cashflow From Financing	-	-	-	15*	14,025	5.00	4,451	-	10,742	-	-	-	8,005	70,935	3,322	22.00	-14.69

REVB Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 4,145,902	$ 5,377,400
General and administrative	4,510,762	5,487,111
Total operating expenses	8,656,664	10,864,511
Loss from operations	(8,656,664)	(10,864,511)
Other income (expense):
Change in fair value of warrant liability	8,328,937	0
Other income (expense)	207,473	34,962
Total other income (expense), net	8,536,410	34,962
Net loss	$ (120,254)	$ (10,829,549)
Net loss per share, basic	$ (0.53)	$ (149.2)
Net loss per share, diluted	$ (0.53)	$ (149.2)
Weighted-average shares used to compute net loss per share, basic	228,641	72,585
Weighted-average shares used to compute net loss per share, diluted	228,641	72,585

REVB Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 11,991,701	$ 5,252,979
Deferred offering costs	71,133	87,171
Prepaid expenses and other current assets	84,691	73,132
Total current assets	12,147,525	5,413,282
Property and equipment, net	65,084	90,133
Total assets	12,212,609	5,503,415
Current liabilities:
Accounts payable	1,359,898	554,205
Accrued expenses	1,152,460	985,497
Warrant liability	141,276
Deferred underwriting commissions	2,911,260	2,911,260
Total current liabilities	5,564,894	4,450,962
Total liabilities	5,564,894	4,450,962
Commitments and Contingencies (Note 4)
Stockholders' equity:
Common Stock, $0.001 par value; 500,000,000 shares authorized at December 31, 2023 and December 31, 2022 and 264,537 and 77,375 issued and outstanding at December 31, 2023 and December 31, 2022, respectively	265	77
Additional paid-in-capital	32,114,552	26,399,224
Accumulated deficit	(25,467,102)	(25,346,848)
Total stockholders' equity	6,647,715	1,052,453
Total liabilities and stockholders' equity	12,212,609	5,503,415
Series A Preferred Stock [Member]
Stockholders' equity:
Preferred stock value	$ 0	$ 0

About Revere Bank

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-100, a potential therapy for the prevention and treatment of healthcare-associated bacterial infection resulting from surgery, severe burns, urinary tract infection, sepsis, and antibiotic resistance; REVTx-200, a potential intranasal therapy; and REVTx-300, a potential therapy for the treatment of chronic organ disease, including chronic kidney disease. It is also developing REVTx-99b, a treatment for food allergies; REVTx-99a, an anti-viral nasal drop solution for the potential prevention or treatment of respiratory viral infection; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, influenza A, influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.

CEO	Mr. James M. Rolke
WEBSITE	revbiosciences.com
INDUSTRY	Biotechnology
EMPLOYEES	6

Revere Bank Frequently Asked Questions

What is the ticker symbol for Revere Bank? What does REVB stand for in stocks?

REVB is the stock ticker symbol of Revere Bank. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Revere Bank (REVB)?

As of Fri Apr 12 2024, market cap of Revere Bank is 13.1 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of REVB stock?

You can check REVB's fair value in chart for subscribers.

What is the fair value of REVB stock?

You can check REVB's fair value in chart for subscribers. The fair value of Revere Bank is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Revere Bank is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for REVB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Revere Bank a good stock to buy?

The fair value guage provides a quick view whether REVB is over valued or under valued. Whether Revere Bank is cheap or expensive depends on the assumptions which impact Revere Bank's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for REVB.

What is Revere Bank's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 12 2024, REVB's PE ratio (Price to Earnings) is -130.98 and Price to Sales (PS) ratio is 2.16 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. REVB PE ratio will change depending on the future growth rate expectations of investors.